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Background: Several observational studies have shown an association between increased
circulating homocysteine and risk of type 2 diabetes (T2D). We aimed to assess whether
this relation is causal using genetic data from large populations of individuals of European
descent.
Methods: We investigated the association between homocysteine concentrations and
blood glucose, plasma insulin, T2D in the Prospective Investigation of the Vasculature in
Uppsala Seniors (PIVUS) cohort (n=1,016). A score of five previously published single
nucleotide polymorphisms (SNPs) from genes involved in homocysteine metabolism were
utilized as genetic instrument for homocysteine concentrations.The effect estimate of this
genetic score with T2D was determined using results from the DIAbetes Genetics Repli-
cation And Meta-analysis (DIAGRAM) consortium (including 34,840 cases and 114,981
controls). Further, the effects of the genetic score with fasting glucose and insulin were
determined using results from the Meta-Analyses of Glucose and Insulin-related traits
Consortium (MAGIC) (up to 38,238 non-diabetic participants).
Results:The genetic score provided a strong instrument for homocysteine concentrations
(P=2.7×10−143, F =650). In the PIVUS cohort, we found an association of homocysteine
with fasting insulin [β=0.056 (95% CI 0.021, 0.090), P=0.001], but not with incident dia-
betes. We did not find any evidence of a causal effect of homocysteine on fasting glucose,
fasting insulin, orT2D (P >0.05 for all analyses) when using data from DIAGRAM or MAGIC
studies.
Conclusion: No evidence of a causal relationship of levels of plasma homocysteine with
fasting glucose, fasting insulin, or T2D was observed.
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INTRODUCTION
Type 2 diabetes (T2D) is one of the most prevalent metabolic
diseases and has already reached epidemic proportion in many
countries (1). A multitude of factors (both genetic and environ-
mental) contribute to the pathogenesis of T2D (2–4). If not treated
adequately, eventual outcomes due to diabetic complications may
be potentially devastating as almost 75% of T2D patients die due
to cardiovascular complications (5).
Homocysteine (Hcy) is a sulfur-containing amino acid and is
generated from the breakdown of the dietary amino acid methio-
nine (6). Different enzymes, encoded by genes in the Hcy metab-
olism pathway, play an important role in regulating the levels of
Hcy. Several candidate and genome-wide association studies have
shown a number of single nucleotide polymorphisms (SNPs) asso-
ciated with modulated levels of Hcy, many of these within or close
to genes implicated in the Hcy metabolic pathway (6–11). Further,
dietary factors such as vitamin B12 and folate also play important
roles in maintaining optimum level of Hcy (6).
Elevated level of Hcy (hyperhomocysteinemia) has been shown
to be a risk factor for cardiovascular diseases and T2D develop-
ment (12, 13). Many studies have also shown association between
increased levels of Hcy with T2D-associated features such as
impaired beta-cell function and insulin resistance (3, 14, 15).
These adverse outcomes in response to hyperhomocysteinemia
have been suggested to be related to various mechanisms such as
oxidative stress and inflammation, contributing components of
T2D pathogenesis (6, 16).
In Mendelian randomization (MR) study designs, one or sev-
eral genetic variants, usually SNPs, associated with exposure to a
modifiable risk factor are used as instrumental variables (IV) to
provide unbiased estimates of the causal relationship of the expo-
sure to the risk factor (here Hcy) with an outcome of interest (here
T2D and related traits) (17). Previous MR studies have provided
conflicting results about causal effect of Hcy on T2D (18–20).
We applied an MR framework utilizing results from
the genome-wide association study (GWAS) meta-analysis
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including up to 34,840 T2D cases (21) and up to 46,186
individuals of European descent (22) with T2D intermedi-
ate trait measures to assess the potential causal relationship
between Hcy and diabetes and related traits. We used data
from a population-based study to compare estimates derived
from causal analyses with estimates derived from conventional
analyses.
MATERIALS AND METHODS
MATERIALS
Prospective Investigation of the Vasculature in Uppsala Seniors
We used data from the Prospective Investigation of the Vasculature
in Uppsala Seniors (PIVUS) study for assessing the association of
Hcy with diabetes and diabetes-related traits. The PIVUS study
has been described in detail elsewhere (23). Briefly, all subjects
aged 70 years living in Uppsala, Sweden were eligible. The subjects
were chosen from the community register and invited in a ran-
domized order from the start of the study in April 2001 to the
last included subject in June 2004. Of the 2,025 subjects invited,
1,016 subjects (507 men and 509 women) agreed to participate
and were included in the study. All the participants gave their
written informed consent and the Ethics committee of Uppsala
University, Uppsala approved the study. Participants underwent
health assessment including questionnaires, clinical examinations,
and a detailed biochemical panel. Participants underwent sub-
sequent examinations at ages 75 and 80 years. During the visit
at age 80 years, all medical records were screened for diagnosis
of diabetes. Biochemical profiling of blood samples collected at
baseline (age 70 years) was performed at the University Hospital,
Uppsala, Sweden. Plasma insulin was measured with a chemi-
luminescence assay (Roche, Basel, Switzerland). Fasting blood
glucose was measured in whole blood utilizing HemoCue instru-
ment (HemoCue, Ängelholm, Sweden) following manufacturer’s
recommendation and recalibrated to plasma concentrations by
multiplying with a factor of 1.11. Diabetes was defined as a
doctor-diagnosed history of diabetes or a fasting blood glucose
≥7.0 mmol/l at the examination. Level of Hcy was measured
using AxisVR Homocysteine Enzyme Immunoassay (Axis-Shield
Diagnostics).
Genetic data
To create genetic instruments, we used results from the largest
GWAS of Hcy levels based on meta-analysis of 44,147 individuals
of European descent (11). In order to achieve a specific instru-
ment and minimize the risk of pleiotropic effects, we excluded
all SNPs mapped to genes outside the Hcy metabolism path-
way, e.g., hepatocyte nuclear factor 1 homeobox A (HNF1A).
Therefore, the final selection included five SNPs from three
loci: 5,10-methylenetetrahydrofolate reductase (MTHFR), 5-
methyltetrahydrofolate-homocysteine methyltransferase (MTR),
and cystathionine-beta-synthase (CBS), where MTHFR and CBS
contained two independent signals each. We assessed the results
for the five selected SNPs from van Meurs et al., where effects
(β) of each SNP were reported in the per-allele effect on lnHcy
(SD-units). The effect estimates of each of the Hcy SNPs on
T2D and diabetes-related traits were collected from GWAS meta-
analysis results – the largest studies available with GWAS data. The
effect on T2D risk was estimated by utilizing a study by DIAbetes
Genetics Replication And Meta-analysis (DIAGRAM) consortium
including 34,840 cases and 114,981 controls (21). We transformed
reported odds ratios for T2D to lnOR scale for further analy-
sis. The effect estimate of each Hcy SNP on measures of glucose
homeostasis was based on associations with fasting glucose in up
to 46,186 non-diabetic participants and fasting insulin in up to
38,238 non-diabetic participants from the Meta-Analyses of Glu-
cose and Insulin-related traits Consortium (MAGIC) (22). Effects
were reported on non-transformed scale for fasting glucose and on
log-transformed scale for fasting insulin. The effect of each SNP is
reported in Table 1.
STATISTICAL ANALYSIS
The association of Hcy plasma concentrations with T2D, fasting
insulin, and fasting glucose
For all analyses in PIVUS, Hcy was transformed to the natural
logarithmic scale and thereafter SD transformed. We assessed the
association of Hcy with ln-transformed insulin and glucose in
non-diabetic subjects from PIVUS using linear regression model-
ing with glycemic traits as the dependent variable adjusting for age
and sex. We used a logistic regression model to assess the potential
Table 1 | Association of Hcy SNPs with diabetes and related traits, based on large genome-wide association studies.
ln Homocysteine T2D Fasting glucose ln Fasting insulin
SNP
Gene rsID EA EAF β SE P β (lnOR) SE P β SE P β SE P
MTHFR rs12134663 C 0.20 0.10 0.01 2.5×10−21 0.01 0.02 0.78 0.002 0.005 0.69 −0.002 0.005 0.63
MTHFR rs1801133 A 0.34 0.16 0.01 4.3×10−104 0.02 0.01 0.10 −0.003 0.004 0.46 −0.005 0.004 0.25
MTR rs2275565 G 0.79 0.05 0.01 2.0×10−10 0.00 0.02 0.93 −0.001 0.005 0.91 −0.003 0.005 0.50
CBS rs234709 C 0.55 0.07 0.01 3.9×10−24 0.01 0.02 0.57 0.003 0.004 0.38 0.003 0.004 0.51
CBS rs2851391 T 0.47 0.06 0.01 1.7×10−12 −0.02 0.02 0.32 −0.001 0.004 0.87 −0.002 0.004 0.66
SCORE 0.09 0.004 2.7×10−143 0.008 0.008 0.34 0.0002 0.002 0.90 −0.002 0.002 0.38
T2D, type 2 diabetes; SNP, single nucleotide polymorphism; MTHFR, methylenetetrahydrofolate reductase; MTR, 5-methyltetrahydrofolate-homocysteine methyl-
transferase; CBS, cystathionine-beta-synthase; EA, effect allele; EAF, effect allele frequency; β, beta; SE, standard error; P, significance; ln(OR), natural log of odds
ratio.
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association with prevalent diabetes at baseline adjusting for age
and sex. We assessed the association of Hcy with incident T2D
using Cox proportional hazard models for time-to-T2D adjusting
for age and sex. Subjects who died during the study period were
censored. The assumption of proportional hazards was assessed by
testing the associations of Schoenfeld residuals and time. We also
performed secondary analysis in a subset of PIVUS samples where
we tested whether adjusting for intake of vitamin B12 and folate
were confounders of Hcy with prevalent (n= 853) and incident
diabetes outcome (n= 750).
Association of genetic score with levels of Hcy
We identified the Hcy-increasing allele of each SNP in the data
together with its reported effect from van Meurs et al. (11) and
used the R-package “gtx” to estimate the combined effect of the
genetic score (βscore_Hcy) on levels of Hcy based on the summary
level data. Briefly, βscore_Hcy was calculated as
∑
β is
−2
i /
∑
s−2i ,
where βi was the effect of the Hcy-increasing risk alleles on Hcy
and s i its corresponding standard error (24). The output of the
equation gives an estimate of the per-allele increase in lnHcy of
the genetic score.
Association of genetic score with T2D, fasting insulin, and fasting
glucose
All analyses were performed using the Hcy-increasing allele
as the effect allele. The effect of the non-weighted genetic
score (βscore_outcome) on the outcomes of interest: T2D, fast-
ing glucose, and fasting insulin, respectively, was calculated as∑
β is
−2
i /
∑
s−2i , where βi is the effect of the Hcy-increasing
risk alleles on T2D or T2D-related trait and s i its corresponding
standard error using the R-package “gtx.”
Instrumental variable analyses
We used IV estimators to quantify the strength of causal asso-
ciation between Hcy and T2D, fasting glucose, and insulin. The
estimator (βIV estimator) was found as a ratio between two regres-
sion coefficients determined from the genetic score analysis (Eq.
1): estimated genetic score on given outcome (βscore_outcome) and
estimated genetic score effect on Hcy (βscore_Hcy).
βIV estimator = βgenetic instrument_outcome
βgenetic instrument_Hcy
(1)
The standard errors (SE) for the IV estimators were calculated
using the delta method (Eq. 2), which we have previously evaluated
for this purpose (25).
SEIV = abs(βIV)
×
√(
SEgenetic instrument_Hcy
βgenetic instrument_Hcy
)2
+
(
SEgenetic instrument_outcome
βgenetic instrument_outcome
)2
(2)
RESULTS
The median age of study participants was 70.2 years and almost
equal percentage of females and males were present.
THE ASSOCIATION BETWEEN LEVELS OF PLASMA Hcy AND T2D,
FASTING INSULIN, AND FASTING GLUCOSE
The baseline characteristics of PIVUS participants are shown in
Table 2. A total of 11% individuals were found to have hyper-
homocysteinemia (levels of Hcy >15.0µmol/L). One-hundred
nineteen individuals had T2D at baseline. Seventy-two individuals
developed T2D during 10 years follow-up. In our PIVUS cohort,
we found no association between levels of Hcy at age 70 years
with prevalent diabetes [odds ratio per SD-unit in ln-transformed
Hcy, OR 0.98 (95% CI 0.80, 1.19),P= 0.80], incident T2D [hazard
ratio, HR 0.79 (95% CI 0.62, 1.004),P-value 0.054], or with fasting
glucose [β=−0.001 (95% CI −0.038, 0.036), P-value 0.96]. Fur-
ther adjustment in the prevalent and incident diabetes models
for intake of vitamin B12 and folate did not change the effect
estimates of Hcy. A significant association was observed between
Table 2 | Baseline characteristics of the PIVUS cohort (n=1,016).
Variable Median (IQR) or number (%)
Clinical variables
Age (years) 70.2 (70.0, 70.3)
Sex (female) 509 (50.2)
Smokers (current) 107 (10.6)
BMI (kg/m2) 26.6 (24.0, 29.7)
WHR (cm) 0.90 (0.86, 0.95)
SBP (mmHg) 148 (134, 164)
DBP (mmHg) 78 (72, 86)
Homocysteine (µmol/L) 9.9 (8.0–12.3)
Glucose (mmol/L) 5.0 (4.6, 5.4)
Insulin (mIU/L) 7.4 (5.2–10.9)
Vit B12 (µg/day)a 6.0 (4.6–7.9)
Vit B6 (mg/day)a 1.8 (1.5–2.1)
Folate (µg/day)a 226 (186–271)
LDL (mmol/L) 3.3 (2.8, 3.9)
HDL (mmol/L) 1.4 (1.2, 1.8)
TG (mmol/L) 1.15 (0.87, 1.51)
GFR (mL/min/1.73m2)b 78.9 (65.4, 94.9)
Exercise habits
No 114 (11.5)
Low 583 (59.0)
Medium 222 (22.5)
High 69 (7.0)
Education
Low 569 (56.7)
Medium 182 (18.1)
High 253 (25.2)
Number (%) is shown for discrete variables while median (IQR) is shown for
continuous variables.
aDietary intake is shown.
bLog-transformed value is reported.
IQR, interquartile range; BMI, body mass index; WHR, waist–hip ratio; SBP, sys-
tolic blood pressure; DBP, diastolic blood pressure;Vit B12,Vitamin B12;Vit B6,Vit-
amin B6; LDL, low-density lipoprotein cholesterol; HDL, high-density lipoprotein
cholesterol; TG, triglycerides; GFR, glomerular filtration rate.
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Table 3 |The association of homocysteine with diabetes and related traits in the PIVUS cohort and in causal analysis using large genome-wide
association studies.
PrevalentT2D IncidentT2D Fasting glucose Fasting insulin
(ln-transformed)
OR SE P HR SE P β SE P β SE P
PIVUS 0.98 0.10 0.80 0.79 0.10 0.054 −0.001 0.02 0.96 0.05 0.02 0.001
IV estimate 1.01 0.09 0.34 0.0002 0.02 0.90 −0.002 0.02 0.38
The effect is given per SD-increase in log-transformed homocysteine.
OR, odds ratio; SE, standard error; HR, hazard ratio; P, significance; β, beta; IV, instrument variable.
levels of Hcy and ln fasting insulin [β= 0.056 (95% CI 0.021,
0.090), P-value 0.001], indicating that 1-SD-unit increase in the
level of lnHcy was associated with 5.6% (e0.056) increase in fasting
insulin (Table 3).
THE ASSOCIATION BETWEEN GENETIC SCORE AND LEVELS OF
PLASMA Hcy
We found a strong association between the genetic score and levels
of plasma Hcy using the published genetic associations (11). We
estimated that each allele of the score increased lnHcy with 0.092
SD (95% CI: 0.084, 0.100; P-value 2.7× 10−143). The calculated
F-statistics for the score was 650.
THE ASSOCIATION BETWEEN GENETIC SCORE AND T2D, FASTING
INSULIN, AND FASTING GLUCOSE
We did not find evidence for an association of the genetic score
with T2D, fasting insulin, or fasting glucose. The estimated odds
ratio for each additional allele of the genetic score was 1.01 (95%
CI 0.99, 1.024; P-value 0.34) for T2D. The estimated per-allele
effect of the genetic score on ln fasting insulin was −0.002 (95%
CI−0.006, 0.002;P-value 0.38) and 0.0002 (95% CI−0.003, 0.004;
P-value 0.90) for fasting glucose (Table 3).
INSTRUMENTAL VARIABLE ANALYSES
We did not find evidence for a causal association of levels of Hcy
with T2D and related traits. The estimated causal odds ratio for
each SD-increase in lnHcy was 1.09 (95% CI 0.92, 1.30; P-value
0.34) for T2D. The estimated causal effect for each SD-increase
of Hcy on ln fasting insulin was −0.019 (95% CI −0.060, 0.023;
P-value 0.335) and 0.002 (95% CI −0.037, 0.042; P-value 1) for
fasting glucose (Table 3).
DISCUSSION
In the present study, we did not observe any evidence of a causal
relationship between genetically predicted homocysteine concen-
trations and T2D development. To the best of our knowledge, we
have included the largest number of individuals with data on the
effect of Hcy-related SNPs on fasting glucose, fasting insulin, and
T2D.
COMPARISONWITH PREVIOUS STUDIES
Type 2 diabetes
Several observational studies have found hyperhomocysteine-
mia to be a risk factor for T2D and related complications (3,
15, 26). However, the results are contradictory and some stud-
ies have shown a null effect (27–29). Our observational data
from PIVUS did not show evidence of increased risk for T2D
with increasing levels of Hcy. On the contrary, our effect esti-
mate was negative, although non-significant (P= 0.054). In a
large, long-term randomized clinical trial by Song et al. involv-
ing 4,252 women at high risk for cardiovascular diseases, lower-
ing Hcy levels through vitamin B6, B12, and folic acid did not
reduce the risk of developing T2D (30). Another possibility to
evaluate the possible causal connection of Hcy with T2D is the
MR approach, where the association of Hcy-related genetic vari-
ants with T2D is evaluated, aiming to assess life-long exposure
to augmented levels of Hcy. A recent MR study by Zhu et al.
assessed whether the MTHFR C677T polymorphism is a risk
factor for T2D in Chinese Han populations (19). The authors
meta-analyzed 29 different case–control studies involving 4,656
T2D cases and 2,127 controls from Chinese population. They
have found MTHFR C677T polymorphism to be a risk factor
for T2D and thereby shown evidence in favor of a causal rela-
tion between Hcy and T2D. The variant allele (T) in MTHFR
gene leads to the formation of thermolabile enzyme with reduced
activity thereby increasing levels of Hcy (31). The distribution
of MTHFR C677T polymorphism differs worldwide with Chi-
nese having higher T allele frequency as compared to Europeans,
Africans, or other Asian populations, such as Japanese and Indi-
ans (8, 32). Since the frequency of this polymorphism varies
even within China, the samples were separated into two major
groups (northern and southern) based on their region, but simi-
lar association results between the polymorphism and T2D were
obtained. In a study by Huang et al., the authors collected data on
the MTHFR C677T polymorphism, Hcy, and T2D in 4,011 T2D
cases and 4,303 controls from published studies (20). The pooled
data from 17 studies from different countries showed a signifi-
cant association of MTHFR C677T polymorphism with levels of
Hcy, as well as with T2D. However, the data were pooled for dif-
ferent ethnicities together and the authors reported significant
heterogeneity among different study groups involved in meta-
analysis. In another study by Zhong et al. involving 4,855 diabetic
patients and 5,242 controls from different ethnic backgrounds
(Asians, Europeans, and Africans), no association between the
Hcy-increasing SNP MTHFR C677T and T2D was observed (18).
Even in the repeated meta-analysis including individuals only from
same ethnic group, similar results were obtained for Europeans
and other populations thereby corroborating our results. The
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conflicting results obtained in our study as compared to the
Chinese study have several possible explanations. Ethnic back-
ground of the study subjects is different and there can be variation
in gene–environment interaction due to several environmental
factors.
Fasting insulin
We observed a significant association between measured levels
of plasma Hcy and fasting insulin in the PIVUS study. Several
observational studies have shown association between Hcy and
insulin resistance (3, 26, 33). In the Framingham offspring study,
Meigs et al. studied 2,011 individuals without CVD or T2D, and
observed significant association between hyperhomocysteinemia
and hyperinsulinemia (3). The results obtained in the causal part
of our study do not support the causal relation between homocys-
teine and fasting insulin concentrations, which indicates that the
observed association between Hcy and insulin in PIVUS and other
studies may be explained by either reverse causation or residual
confounding.
Fasting glucose
We did not observe an association between level of Hcy and
blood glucose, in the observational analyses in PIVUS, or in the
IV analyses using large-scale data from the MAGIC consortium.
Several other observational studies have been performed to under-
stand the relation between Hcy and glucose (34–38). Our study
corroborates the results obtained in earlier studies.
Strengths and limitations
The strengths of this study are the inclusion of a large number
of individuals and the use of multiple SNPs from Hcy metabo-
lism pathway in the causal analysis, which increases the statistical
power of our study. To the best of our knowledge, this is the
first MR study that has comprehensively evaluated the associa-
tion of multiple SNPs from Hcy metabolism pathway with levels
of fasting glucose, fasting insulin and T2D in large number of indi-
viduals. Although genetic variants in the gene hepatocyte nuclear
factor 1-alpha (HNF1A) are associated with Hcy, we chose not to
include it in the genetic IV, because of its function in the regulating
expression of several liver and pancreatic-islet specific genes and its
association with MODY type 3. Due to the regulating action of this
gene on several other genes, pleiotropic effects may not be ruled
out thereby making this gene unfavorable for inclusion into MR
studies. Nevertheless, our study also have potential limitations,
which are mainly connected to the validity of the assumptions
underlying the causal interpretation within MR. There are three
main assumptions for a MR study: (1) independence between the
instrument and confounders, i.e., genotypes are randomized; (2) a
reliable association between the genetic variant and intermediate
phenotype; and (3) conditional independence between the genetic
variant and the outcome, given the intermediate phenotype and
the confounders, i.e., no pleiotropy. Neither the first nor the third
assumption can be tested statistically in the observed data using
single genotypes as IV, and conclusions about these have to be
based on previous biological knowledge. In the present study, we
have used only robustly associated SNPs from large GWAS that
reside in genes from the Hcy metabolic pathway, and we therefore
regard the instrument as specific and non-pleiotropic. The ran-
dom distribution of genotypes in the population is the very basis of
MR and could be violated if separate ethnic groups with different
allele frequencies were analyzed together without accounting for
the population substructure. In the present study, all association
analysis was done using published GWAS of individuals of Euro-
pean descent. In these studies, extensive work has been made to
identify and correct for population stratification. Concerning the
reliability of the second assumption (association between genetic
score and Hcy), the strength of the association was high.
CONCLUSION
In conclusion, although a strong association of Hcy with fasting
insulin was noted in non-diabetics in observational analyses, we
did not find any evidence of a causal link between Hcy with insulin,
glucose, or T2D.
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